Trial Profile
To evaluate the comparative effectiveness of Tofacitinib and biological DMARDs in clinical practice in Patients with Rheumatoid Arthritis with Insufficient Response to Subcutaneous Methotrexate
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2018
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary) ; Abatacept; Adalimumab; Certolizumab pegol; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms REMARCA
- 13 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism